128 related articles for article (PubMed ID: 28480767)
1. Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate-resistant polycystic ovary disease.
Seyam E; Hasan M; Khalifa EM; Ramadan A; Hefzy E
Gynecol Endocrinol; 2017 Nov; 33(11):892-898. PubMed ID: 28480767
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease.
Seyam E; Hefzy E
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():126-133. PubMed ID: 29408743
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease.
Tiitinen AE; Laatikainen TJ; Seppälä MT
Fertil Steril; 1993 Jul; 60(1):58-62. PubMed ID: 7685718
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
5. Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling.
Abuelghar WM; Bayoumy HA; Ellaithy MI; Khalil MS
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():178-85. PubMed ID: 24576485
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
Seyam E; Hefzy E
Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome.
Pawelczak M; Rosenthal J; Milla S; Liu YH; Shah B
J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):356-9. PubMed ID: 25256873
[TBL] [Abstract][Full Text] [Related]
8. Endocrine changes after laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovarian syndrome.
Al-Ojaimi EH
Saudi Med J; 2004 Aug; 25(8):1032-9. PubMed ID: 15322594
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease.
Espinosa de los Monteros A; Ayala J; Sanabria LC; Parra A
Rev Invest Clin; 1995; 47(5):347-53. PubMed ID: 8584804
[TBL] [Abstract][Full Text] [Related]
11. Does ischaemia-modified albumin level predict clomiphene citrate resistant polycystic ovary syndrome patients?
Ege S; Bademkıran MH; Peker N; Erdem S; Köçeroğlu R; Erel Ö
J Obstet Gynaecol; 2021 Apr; 41(3):462-466. PubMed ID: 32799715
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome.
Mohsen IA
Gynecol Endocrinol; 2012 Apr; 28(4):269-72. PubMed ID: 21970545
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.
Rouzi AA; Ardawi MS
Fertil Steril; 2006 Feb; 85(2):428-35. PubMed ID: 16595222
[TBL] [Abstract][Full Text] [Related]
14. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
[TBL] [Abstract][Full Text] [Related]
15. l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.
El Sharkwy I; Sharaf El-Din M
Gynecol Endocrinol; 2019 Aug; 35(8):701-705. PubMed ID: 30806102
[TBL] [Abstract][Full Text] [Related]
16. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
Parsanezhad ME; Alborzi S; Namavar Jahromi B
Arch Gynecol Obstet; 2004 Jan; 269(2):125-9. PubMed ID: 14648180
[TBL] [Abstract][Full Text] [Related]
17. The effect of clomiphene citrate on oxidative stress parameters in polycystic ovarian syndrome.
Peker N; Turan G; Ege S; Bademkıran MH; Karaçor T; Erel Ö
J Obstet Gynaecol; 2021 Jan; 41(1):112-117. PubMed ID: 32131660
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index.
Samy N; Hashim M; Sayed M; Said M
Dis Markers; 2009; 26(4):163-70. PubMed ID: 19729797
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum concentration of anti-Müllerian hormone in obese women with polycystic ovary syndrome.
El-Halawaty S; Rizk A; Kamal M; Aboulhassan M; Al-Sawah H; Noah O; Al-Inany H
Reprod Biomed Online; 2007 Nov; 15(5):495-9. PubMed ID: 18028738
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
Anttila L; Ding YQ; Ruutiainen K; Erkkola R; Irjala K; Huhtaniemi I
Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
